HRTS Fact Sheet: Tema Heart & Health ETF
Share
$37.75
close, Nov 18, 2026
Over the year to Nov 18, 2026, HRTS returned +10.3% in total and charged 0.75% a year.
- 1-year total return
- +10.3%
- to Nov 18, 2026
- Expense ratio
- 0.75%
- a year
- Net assets
- $57m
- on Nov 17, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
HRTS $11,025 +10.3% · VOO $11,188 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+2.3%
3 months−2.9%
Year to date+7.0%
1 year+10.3%
Since launch+45.8%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
ELI LILLY & CO12.63%
THERMO FISHER SCIENTIFIC INC5.43%
ROCHE HOLDING AG4.39%
MERCK & CO INC4.06%
BRIDGEBIO PHARMA INC3.80%
KODIAK SCIENCES INC3.78%
GILEAD SCIENCES INC3.52%
DANAHER CORP3.15%
REVOLUTION MEDICINES INC3.05%
NOVO NORDISK A/S2.99%
HRTS top ten by weight, 46.8% of the fund, of its 45 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Actively managed · First traded Nov 21, 2023 · Benchmark Its own holdings, as of Nov 17, 2026